The USA Antibody-Drug Conjugates Market - Forecasts from 2019 to 2024
The USA antibody-drug conjugates (ADCs) market is expected to grow with a CAGR of 27.51 percent to achieve a market size of USD5,318.400 million by the end of 2024. The antibody-drug conjugate technology provides a promising and effective strategy for targeted cancer treatment, hence promoting market growth during the forecast period in the United States. The Seattle Genetics, which is a biotechnology company headquartered in Bothell, Washington has an antibody-drug conjugate drug named as ADCETRIS®, this has gained approval for treating lymphomas expressing CD30. The company has retained its commercial rights for drug sales in the United States and Canada only. While in collaboration with Takeda Pharmaceutical Company Limited, the company sells ADCETRIS in countries other than the US and Canada. Such joint initiatives by the companies in the country will provide an opportunity for the market to grow in the forecast period and in the coming years with the growing incidences of cancer in the United States and other parts of the world. Furthermore, the United States has the highest health expenditure among the industrialized regions of the world, promoting the growth of the ADC market during the forecast period with the growing innovations in cancer therapy.
The USA antibody-drug conjugates Market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by the target and by indication.
The USA antibody-drug conjugates market on segmented based on target and indication. Based on target the market has been segmented into CD 30, CD 22, and HER 2. By indication, the market is segmented into haematologic malignancies and non-haematologic malignancies.
Major players in the USA antibody-drug conjugates market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the USA antibody-drug conjugates market.
Segmentation
The USA antibody-drug conjugates market has been analyzed through the following segments:
The USA antibody-drug conjugates Market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by the target and by indication.
The USA antibody-drug conjugates market on segmented based on target and indication. Based on target the market has been segmented into CD 30, CD 22, and HER 2. By indication, the market is segmented into haematologic malignancies and non-haematologic malignancies.
Major players in the USA antibody-drug conjugates market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the USA antibody-drug conjugates market.
Segmentation
The USA antibody-drug conjugates market has been analyzed through the following segments:
- By Target
- CD 30
- CD 22
- HER 2
- By Indication
- Haematologic Malignancies
- Non-Haematologic Malignancies
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
5. USA ANTIBODY-DRUG CONJUGATES MARKET BY TARGET
5.1. CD
5.2. CD
5.3. HER
6. USA ANTIBODY-DRUG CONJUGATES MARKET BY INDICATION
6.1. Haematologic Malignancies
6.2. Non Haematologic Malignancies
7. COMPETITIVE INTELLIGENCE
7.1. Market Positioning Matrix and Ranking
7.2. Recent Investments and Deals
7.3. Strategies of Key Players
8. COMPANY PROFILES
8.1.Takeda Pharmaceutical Company Limited
8.2. F. Hoffmann-La Roche Ltd.
8.3. Pfizer Inc.
8.4. Astellas Pharma Inc.
8.5. Seattle Genetics, Inc.
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
5. USA ANTIBODY-DRUG CONJUGATES MARKET BY TARGET
5.1. CD
5.2. CD
5.3. HER
6. USA ANTIBODY-DRUG CONJUGATES MARKET BY INDICATION
6.1. Haematologic Malignancies
6.2. Non Haematologic Malignancies
7. COMPETITIVE INTELLIGENCE
7.1. Market Positioning Matrix and Ranking
7.2. Recent Investments and Deals
7.3. Strategies of Key Players
8. COMPANY PROFILES
8.1.Takeda Pharmaceutical Company Limited
8.2. F. Hoffmann-La Roche Ltd.
8.3. Pfizer Inc.
8.4. Astellas Pharma Inc.
8.5. Seattle Genetics, Inc.
